(FLAIR) Fluid attenuation inversion recovery is a special inversion recovery sequence with long TI to remove the effects of fluid from the resulting images. The TI time of the FLAIR pulse sequence is adjusted to the relaxation time of the component that should be suppressed. For fluid suppression the inversion time (long TI) is set to the zero crossing point of fluid, resulting in the signal being 'erased'.
Lesions that are normally covered by bright fluid signals using conventional T2 contrast are made visible by the dark fluid technique FLAIR is an important technique for the differentiation of brain and spine lesions.

See also Inversion Recovery.

(FID) A free induction decay curve is generated as excited nuclei relax. The amplitude of the FID signal becomes smaller over time as net magnetization returns to equilibrium. If transverse magnetization of the spins is produced, e.g. by a 90° pulse, a transient MR signal will result that will decay toward zero with a characteristic time constant T2 (or T2*); this decaying signal is the free induction decay.
The signal peaks of the echoes fall onto this T2 decay curve, while at each echo the signals arise and decay with T2*. The typical T2 relaxation times being of the order of 5-200 ms in the human body. The first part of the FID is not observable (named the 'receiver dead time') caused by residual effects of the powerful exciting radio frequency pulse on the electronics of the receiver.

Short name: Gd-BOPTA, generic name: Gadobenate dimeglumine
A paramagnetic MRI contrast agent (small molecular weight Gd-chelate) with 0.5 and 0.25 molar concentration.
The albumin-mediated relaxation enhancement may result in advantages for Gd-BOPTA over Gd-DTPA and other gadolinium agents in poorly vascularized, small, or lesions with low enhancement and in tumors with high concentrations of albumin. The substance is excreted partly by the kidneys (75-90%), partly by the biliary system (10-25%). The uptake in the liver is about 5% in humans. It is bolus injectable.

See Contrast Agents and MultiHance®.

Gadolinium oxide (Gd2O3) is a prototype paramagnetic agent for contrast enhanced MRI. Gd2O3 particles have very high relaxivity. With its high magnetic moment, gadolinium reduces the relaxation time and enhance MR signal intensity. All gadolinium compounds are highly toxic. Very stable complexes are developed to eliminate the toxicity. See also Paramagnetic Substance, Paramagnetism, Paramagnetic Contrast Agents and Contrast Agents, the info sheet gives an overview and more in-dept information about different types of MRI Contrast media.

Paramagnetic substances, for example Gd-DTPA solutions, are used as MRI oral contrast agents in gastrointestinal imaging to depict the lumen of the digestive organs. Different Gd-DTPA solutions or zeolites containing gadolinium can be used e.g., for diagnosis of delayed gastric emptying, diagnosis of Crohn's disease etc.
Low concentrations of gastrointestinal paramagnetic contrast agents cause a reduction in T1 relaxation time; consequently, these agents act on T1 weighted images by increasing the signal intensity of the bowel lumen. High concentrations cause T2 shortening by decreasing the signal, similar to superparamagnetic iron oxide. Gd-DTPA chelates are unstable at the low pH in the stomach, therefore buffering is necessary for oral use.

See also Gadopentetate Gastrointestinal, Gadolinium Zeolite, Negative Oral Contrast Agents, Gastrointestinal Superparamagnetic Contrast Agents, and Ferric ammonium citrate.